Strategic partnerships OncoPower already collaborates with cost containment players (Mark Cuban Cost Plus Drug Company) to provide pricing and ordering of medications, suggesting a proven pathway for channel partnerships with similar pharmacy or payer entities to expand access and drive patient engagement.

Enterprise tools The availability of enterprise level clinical tools for reimbursed RPM and ePRO patient management indicates a ready-to-sell value proposition to provider networks and healthcare organizations seeking integrated remote monitoring and patient-reported outcomes.

Affordability angle Partnerships around pricing transparency and affordable generics position OncoPower as a cost-saving ally for cancer care—a compelling pitch to hospitals, clinics, and insurer customers aiming to reduce total cost of care.

Diverse touchpoints With a patient-facing app, clinician tools, and a provider-facing portal, there are multiple buyer personas (patients, oncologists, hospital IT, payer accounts) to target with tailored pilot programs or integrated offerings.

Growth readiness Recent partnerships and a funding base indicate momentum and scalability potential; sales efforts can focus on expanding enterprise deployments, white-labeled solutions, or referral arrangements with large cancer centers and health systems.